VMD:NASDAQViemed Healthcare, Inc. Analysis
Data as of 2026-09-01 - not real-time
$8.84
Latest Price
8/10Risk
Risk Level: High
Executive Summary
Viemed Healthcare, Inc. is priced at $8.84, and its moving averages give no clean directional read — the structure is neutral. It has lost 26.1% over the past 30 days. With RSI at 33.4 the momentum picture is approaching oversold, alongside a bullish MACD signal. Price has been bracketed by support at $8.51 and resistance at $10.56.
Multiples put this in undervalued territory: 24.6 times earnings against the sector's 30.4. Consensus targets land 41.4% above where the shares trade now. Revenue is growing at 23.9% on a 4.8% profit margin.
Risk comes out at 8 of a possible 10, a high reading. With 30-day volatility of 58.3%, a beta of 0.27 and a maximum drawdown of 30.5%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
Near-term and long-term part ways here — hold short-term against buy longer out, with 5/10 conviction on the long call.
Multiples put this in undervalued territory: 24.6 times earnings against the sector's 30.4. Consensus targets land 41.4% above where the shares trade now. Revenue is growing at 23.9% on a 4.8% profit margin.
Risk comes out at 8 of a possible 10, a high reading. With 30-day volatility of 58.3%, a beta of 0.27 and a maximum drawdown of 30.5%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
Near-term and long-term part ways here — hold short-term against buy longer out, with 5/10 conviction on the long call.
Top Market Events
Viemed Healthcare Inc VMD posts 24% revenue growth to $78.Viemed Healthcare VMD delivered earnings and revenue surprises of -30.LAFAYETTE, LA / ACCESS Newswire / August 3, 2026 / Viemed Healthcare, Inc.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 3/10
Key Factors
- Trading below the 200-day average of 9.09
- MACD momentum is positive
- 30-day price change of -26.1%
Medium Term
1–3 yearsPositive
Model confidence: 4/10
Key Factors
- P/E of 24.6 versus sector average of 30.4
- Trading below the 200-day average of 9.09
- Analyst targets imply +41.4% versus the current price
Long Term
> 3 yearsPositive
Model confidence: 5/10
Key Factors
- P/E of 24.6 versus sector average of 30.4
- Analyst targets imply +41.4% versus the current price
- Revenue growth of +23.9%
Key Metrics & Analysis
Financial Health
Revenue Growth23.90%
Profit Margin4.81%
P/E Ratio24.6
ROE10.45%
ROA8.21%
Debt/Equity7.95
P/B Ratio2.3
Op. Cash Flow$60.8M
Free Cash Flow$28.3M
Industry P/E30.4
Technical Analysis
TrendNeutral
RSI33.4
Support$8.51
Resistance$10.56
MA 20$9.19
MA 50$10.77
MA 200$9.09
MACDBullish
VolumeDecreasing
Fear & Greed Index93.09
Valuation
Fair Value$24.71
Target Price$12.50
Upside/Downside41.40%
GradeUndervalued
TypeGrowth
Risk Assessment
Beta0.27
Volatility58.31%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.